DoW Peer Reviewed Cancer, Clinical Trial Award

Defense Health Agency Contracting Activity - DHACAAmount not specifiedDue Oct 5, 2026

Researchers Schools & universities Broad eligibility

Deadline: Oct 5, 2026
Posted: May 6, 2026
Award amount: Amount not specified
Focus areas: Science and Technology and other Research and Development

Don’t miss this deadline

We’ll email you before Oct 5, 2026 so you have time to apply.

In plain English

This Department of War (Defense Health Agency) Peer Reviewed Cancer Research Program Clinical Trial Award funds clinical trials (phase 0 through phase III) testing new products, drugs, devices, or approaches to treat or manage cancer within designated topic areas. Applications must include a clinical trial and patient advocates, animal studies are not allowed, and any required IND/IDE regulatory application must be submitted by the application deadline. Eligibility is described as unrestricted (open to any standard entity type), subject to clarification in the program announcement. No specific award amount is stated in this record.

AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.

Who can apply

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

About this grant

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations. Distinctive Features: • Applications to this award mechanism must include a clinical trial. • Projects can range from phase 0 to phase III. • If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial. • Applications are required to include patient advocates. • Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.

Let AI draft your application

Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.

Application Kit — $49 one-time

Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.

Get the Application Kit →

Related grants

Other open grants funding Science and Technology and other Research and Development — soonest deadline first.

Also listed under Defense Health Agency Contracting Activity - DHACA and Science & Research Grants.

Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.